Analyst consensus rating
OnKure Therapeutics Analyst Rating: none
Direct answer
OnKure Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $15.50.
Forecast evidence checked September 4, 2026.
Get free OnKure Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.57
- Average price target
- $15.50
- High price target
- $21.00
- Low price target
- $11.00
- Low target gap
- +208.1%
- Target upside
- +334.2%
- High target gap
- +488.2%
- Target range width
- 280.1%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- September 4, 2026
- Valid through
- September 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for OnKure Therapeutics?
OnKure Therapeutics has a verified none consensus. The same dataset has an average price target of $15.50.
How far are OnKure Therapeutics's low and high targets from the recorded price?
The low target implies +208.1%, while the high target implies +488.2%.
How many analysts are included in OnKure Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is OnKure Therapeutics's target upside or downside calculated?
The average target of $15.50 is divided by the recorded price of $3.57, then one is subtracted to produce +334.2%. This does not guarantee a future return.
When was OnKure Therapeutics's analyst forecast verified?
The data was verified on 2026-09-04. The dataset is valid through 2026-09-11.